COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01685983
Recruitment Status : Completed
First Posted : September 17, 2012
Results First Posted : May 23, 2016
Last Update Posted : March 15, 2019
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastatic-castration resistant prostate cancer (mCRPC) and with disease progression following treatment with a docetaxel-containing chemotherapy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Abiraterone acetate Drug: Prednisolone Phase 2

Detailed Description:
This is an open-label (all people know the identity of the intervention), multicenter, single arm (only one treatment group) study to evaluate the efficacy and safety of abiraterone acetate in patients with mCRPC. The study will be divided into screening phase (up to 28 days before enrollment), treatment phase including treatment cycles (each cycle of treatment will be 28 days), and follow-up phase. Approximately 80 patients will be enrolled into this study. Safety evaluations for adverse events, clinical laboratory tests, electrocardiogram and vital signs as well as pharmacokinetic (what the body does to drug) assessments will be conducted in this study. Patients will continue to receive abiraterone acetate plus prednisolone until disease progression or occurrence of unacceptable toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy.
Actual Study Start Date : August 30, 2011
Actual Primary Completion Date : January 24, 2013
Actual Study Completion Date : March 6, 2018

Arm Intervention/treatment
Experimental: Abiraterone actetate and Prednisolone Drug: Abiraterone acetate
Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
Other Name: JNJ-212082

Drug: Prednisolone
Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.

Primary Outcome Measures :
  1. Percentage of Participants With Prostate-specific Antigen (PSA) Response [ Time Frame: Baseline, Month 4 ]
    The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: Up to 3 Years ]
    Overall survival is defined as the time interval from the date of the first dose to the date of death due to any reason.

  2. Time to PSA Progression [ Time Frame: Up to 28 Months ]
    Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined in the protocol-specific PSAWG criteria. For participants who have achieved a greater than or equal to (>=) 50% decrease from the baseline PSA, assessment of time to disease progression is when the PSA has increased 50% above the nadir and at a minimum of 5 nanogram/mililiter (ng/mL). For participants without a PSA decrease of this magnitude or without a decrease, the time for progression is calculated at the time a 25% increase from baseline PSA has been achieved.

  3. Percentage of Participants With Objective Radiographic Response [ Time Frame: Up to 3 Years ]
    Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

  4. Serum Testosterone [ Time Frame: Baseline and End-of-Treatment Visit (up to approximately 3 years) ]
    Median serum testosterone concentration was reported at baseline and End-of-Treatment visit.

  5. Dehydroepiandrosterone Sulfate (DHEA-S) [ Time Frame: Baseline and End-of-Treatment Visit (up to approximately 3 years) ]
    Median DHEA-S concentration was reported at baseline and End-of-Treatment visit.

  6. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 3 Years ]
    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the prostate (stage IV)
  • Has documented Prostate Specific Antigen (PSA) progression according to protocol-specific prostate specific antigen working group (PSAWG) eligibility criteria
  • Has undergone prior chemotherapy for prostate cancer with regimen(s) containing Docetaxel
  • Has an ongoing androgen deprivation with serum testosterone less than 50 ng/dL
  • Has not received radiotherapy, chemotherapy, or immunotherapy at least 30 days prior to the treatment
  • Eastern Cooperative Oncology Group Performance Status less than or equal to 2

Exclusion Criteria:

  • Active or uncontrolled autoimmune disease that may require corticosteroid therapy
  • Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
  • Uncontrolled hypertension
  • Hemoglobin less than or equal to 9.0 g/dL independent of transfusion
  • Has abnormal liver function tests
  • Surgery or local prostatic intervention within 30 days of the first dose

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01685983

Layout table for location information
Korea, Republic of
Busan, Korea, Republic of
Cheongju-Si, Korea, Republic of
Seongnam-Si, Gyeonggi-Do, Korea, Republic of
Seoul, Korea, Republic of
Kaohsiung, Taiwan
Taichung City, Taiwan
Taichung, Taiwan
Taipei, Taiwan
Taoyuan County, Taiwan
Sponsors and Collaborators
Janssen Research & Development, LLC
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC Identifier: NCT01685983    
Other Study ID Numbers: CR100009
212082PCR2007 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: September 17, 2012    Key Record Dates
Results First Posted: May 23, 2016
Last Update Posted: March 15, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Janssen Research & Development, LLC:
Prostate Cancer
Metastatic-castration resistant prostate cancer
Prostate specific antigen
Abiraterone acetate
Androgen Deprivation
Docetaxel-based chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone acetate
Abiraterone Acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Autonomic Agents